Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Guerci

Showing results (61-70 of 113) with videos related to

Pageof 12
Sort By:
Diabetes Technology & Therapeutics|August 5, 2015
The Impact of Insulin Pump Therapy on Glycemic Profiles in Patients with Type 2 Diabetes: Data from the OpT2mise StudyIgnacio Conget, Javier Castaneda, Goran Petrovski, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 11, 2013
Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICEChantal Mathieu, Claes-Göran Ostenson, Stephan Matthaei, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|August 1, 2022
Sensor-Augmented Insulin Pump with Predictive Low-Glucose Suspend (PLGS): Determining Optimal Settings of Pump and Sensor in a Multicenter Cohort of Patients with Type 1 DiabetesMichael Joubert, Anaïs R Briant, Laurence Kessler, et al.
Journal of Diabetes Science and Technology|August 1, 2014
Accuracy of a new patch pump based on a microelectromechanical system (MEMS) compared to other commercially available insulin pumps: results of the first in vitro and in vivo studiesSophie Borot, Sylvia Franc, Justine Cristante, et al.
Lancet (London, England)|June 12, 2012
Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trialBaptist Gallwitz, Juan Guzman, Francesco Dotta, et al.
Surgery|April 5, 2022
Insulin resistance is more severe in patients with primary hyperparathyroidismAshwaq Al-Jehani, Feras Al-Ahmed, Phi-Linh Nguyen-Thi, et al.
Diabetes, Obesity & Metabolism|July 25, 2022
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 monthsBruno Guerci, Francesco Giorgino, Hélène Sapin, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|May 14, 2013
Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countriesClaes-Göran Ostenson, Stephan Matthaei, Matthew Reaney, et al.
Clinicoeconomics and Outcomes Research : CEOR|July 23, 2013
Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE studyUrpo Kiiskinen, Stephan Matthaei, Matthew Reaney, et al.
Diabetes, Obesity & Metabolism|April 23, 2017
Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponentsMelanie J Davies, Lawrence A Leiter, Bruno Guerci, et al.
Pageof 12

Showing results (61-70 of 113) with videos related to

Sort By:
Pageof 12
Diabetes Technology & Therapeutics|August 5, 2015
The Impact of Insulin Pump Therapy on Glycemic Profiles in Patients with Type 2 Diabetes: Data from the OpT2mise StudyIgnacio Conget, Javier Castaneda, Goran Petrovski, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 11, 2013
Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICEChantal Mathieu, Claes-Göran Ostenson, Stephan Matthaei, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|August 1, 2022
Sensor-Augmented Insulin Pump with Predictive Low-Glucose Suspend (PLGS): Determining Optimal Settings of Pump and Sensor in a Multicenter Cohort of Patients with Type 1 DiabetesMichael Joubert, Anaïs R Briant, Laurence Kessler, et al.
Journal of Diabetes Science and Technology|August 1, 2014
Accuracy of a new patch pump based on a microelectromechanical system (MEMS) compared to other commercially available insulin pumps: results of the first in vitro and in vivo studiesSophie Borot, Sylvia Franc, Justine Cristante, et al.
Lancet (London, England)|June 12, 2012
Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trialBaptist Gallwitz, Juan Guzman, Francesco Dotta, et al.
Surgery|April 5, 2022
Insulin resistance is more severe in patients with primary hyperparathyroidismAshwaq Al-Jehani, Feras Al-Ahmed, Phi-Linh Nguyen-Thi, et al.
Diabetes, Obesity & Metabolism|July 25, 2022
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 monthsBruno Guerci, Francesco Giorgino, Hélène Sapin, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|May 14, 2013
Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countriesClaes-Göran Ostenson, Stephan Matthaei, Matthew Reaney, et al.
Clinicoeconomics and Outcomes Research : CEOR|July 23, 2013
Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE studyUrpo Kiiskinen, Stephan Matthaei, Matthew Reaney, et al.
Diabetes, Obesity & Metabolism|April 23, 2017
Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponentsMelanie J Davies, Lawrence A Leiter, Bruno Guerci, et al.
Pageof 12